<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823377</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2020-05</org_study_id>
    <nct_id>NCT04823377</nct_id>
  </id_info>
  <brief_title>Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.</brief_title>
  <acronym>PACT-01</acronym>
  <official_title>Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sequential comparative prospective interventional study evaluating the impact of the use of&#xD;
      an optimization device of the decision of cancer treatment on aggressiveness of end of life&#xD;
      care. Comparison between a first period, period (A), of care as usual and a second period,&#xD;
      period (B), of systematic and iterative use of a device for optimizing the decision to&#xD;
      continue an anti-cancer treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to study the optimization of this decision process in an advanced Non-Small-Cell&#xD;
      Lung Carcinoma (NSCLC) population, with a Performance Status (PS) ≥ 2 (median survival of&#xD;
      approximately 3 months) piloting iteratively (before each decision to continue treatment) a&#xD;
      process consisting of an evaluation framework (30 items to be answered by the oncologist with&#xD;
      the patient), consolidating:&#xD;
&#xD;
        1. clinical parameters;&#xD;
&#xD;
        2. doctors' expectations regarding the continuation of anticancer treatment;&#xD;
&#xD;
        3. patient expectations and preferences;&#xD;
&#xD;
        4. the possibility of referring the patient to a supportive care specialist and&#xD;
           strengthening home care.&#xD;
&#xD;
      The process triggers a dialogue between the patient and the oncologist, based on facts and&#xD;
      seeks objectivity, ultimately allowing a shared decision.&#xD;
&#xD;
      In this prospective comparative study, the rate of systemic oncological treatment during the&#xD;
      last month of life will be measured consecutively, over a period of usual management,&#xD;
      followed by a period of systematic application of a process of optimization of the medical&#xD;
      decision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>In this prospective comparative study, the rate of systemic oncological treatment during the last month of life will be measured consecutively, over a period of usual management, followed by a period of systematic application of a process of optimization of the medical decision.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients receiving systemic anticancer treatment in their last days of life</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of the percentage of patients receiving systemic anticancer treatment in their last 30 days of life during each period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of chemotherapy</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of chemotherapy (IV, oral) administered in the last 60, 30 and 14 days of life,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emergency room visits</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of patients visiting emergency room visits more than once and of unplanned hospitalizations and intensive care admission in the last month of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of initiation of a new line of chemotherapy</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of initiation of a new line of chemotherapy (IV, oral) in the last month of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of immunotherapy and of Tyrosine kinase inhibitor</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of immunotherapy and of Tyrosine kinase inhibitor in the last 60, 30 and 14 days of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of initiation of Tyrosine kinase inhibitor or immunotherapy</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of initiation of Tyrosine kinase inhibitor or immunotherapy in the last month of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of supportive care</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency and precocity of use of supportive care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival (OS) defined as the time from the date of inclusion to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using QLQ-C15-PAL EORTC (European Organization for Research and Treatment of Cancer) and anxiety with HAD (Hospital Anxiety and Depression) questionnaire</measure>
    <time_frame>24 months</time_frame>
    <description>The quality of Life in palliative cancer care patients will be collected with QLQ-C15-PAL EORTC scale and anxiety will be mesured with HAD scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">364</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Period A: Usual management</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period of end-of-life care as usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period B: Process of optimization of the medical decision</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period of systematic and iterative use of a device for optimizing the decision to continue an anti-cancer treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Patients receiving systemic anticancer treatment in their last days of life</description>
    <arm_group_label>Period A: Usual management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimization of the medical decision</intervention_name>
    <description>Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care</description>
    <arm_group_label>Period B: Process of optimization of the medical decision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically proven metastatic non-small-cell lung carcinoma&#xD;
             (NSCLC) after at least one line of chemotherapy (with or without immunotherapy)&#xD;
             including NSCLC with oncogene addiction.&#xD;
&#xD;
          2. ECOG Performance Status ≥ 2.&#xD;
&#xD;
          3. Age ≥ 18.&#xD;
&#xD;
          4. Written informed consent.&#xD;
&#xD;
          5. Patient capable, according to the investigator, to comply with the requirements of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Small Cell Lung Cancer (including mixed forms).&#xD;
&#xD;
          2. Patient with NSCLC for whom a decision has already been made to permanently&#xD;
             discontinue all systemic cancer treatment.&#xD;
&#xD;
          3. Impossible follow up for geographical, social or psychological reason.&#xD;
&#xD;
          4. Inability to answer a questionnaire (language or neurological barrier).&#xD;
&#xD;
          5. Patient under guardianship.&#xD;
&#xD;
          6. Patient being treated in a therapeutic trial.&#xD;
&#xD;
          7. Patient not covered by social security. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Ange MASSIANI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Ange MASSIANI, MD</last_name>
    <phone>+33 1 47 11 15 15</phone>
    <email>marieange.massiani@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle TURBIEZ</last_name>
    <phone>+33 1 47 11 15 15</phone>
    <email>isabelle.turbiez@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Abbeville</name>
      <address>
        <city>Abbeville</city>
        <zip>80142</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier LELEU, MD</last_name>
      <email>leleu.olivier@ch-abbeville.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier LELEU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH du Pays d'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie MARTINEZ, MD</last_name>
      <email>smartinez@ch-aix.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie MARTINEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire POULET, MD</last_name>
      <email>poulet.claire@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Claire POULET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José HUREAUX, MD</last_name>
      <email>jose.hureaux@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>José HUREAUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Metz-Thionville - Hôpital de Mercy</name>
      <address>
        <city>Ars-Laquenexy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadine PAILLOT, MD</last_name>
      <email>n.paillot@chr-metz-thionville.fr</email>
    </contact>
    <investigator>
      <last_name>Nadine PAILLOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Henri Duffaut Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas CLOAREC, MD</last_name>
      <email>cloarec.nicolas@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas CLOAREC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali RAVOIRE, MD</last_name>
      <email>m.ravoire@isc84.org</email>
    </contact>
    <investigator>
      <last_name>Magali RAVOIRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
      <email>etienne.giroux-leprieur@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI de Compiègne-Noyon</name>
      <address>
        <city>Compiègne</city>
        <zip>60200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie DEHETTE, MD</last_name>
      <email>s.dehette@ch-compiegnenoyon.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie DEHETTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion LOZACH-BRUGIRARD, MD</last_name>
      <email>marion.lozach@chsf.fr</email>
    </contact>
    <investigator>
      <last_name>Marion LOZACH-BRUGIRARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des Cèdres</name>
      <address>
        <city>Cornebarrieu</city>
        <zip>31700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioana CARPIUC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ioana CARPIUC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle MONNET, MD</last_name>
      <email>isabelle.monnet@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle MONNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Claire TOFFART, MD</last_name>
      <email>atoffart@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Claire TOFFART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyril GUIBERT, MD</last_name>
      <email>cyril.guibert@chd-vendée.fr</email>
    </contact>
    <investigator>
      <last_name>Cyril GUIBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier DHALLUIN, MD</last_name>
      <email>xavier.dhalluin@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier DHALLUIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bénédict MASTROIANNI, MD</last_name>
      <email>benedict.mastroianni@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Bénédict MASTROIANNI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HP-HM Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale TOMASINI, MD</last_name>
      <email>pascale.tomasini@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale TOMASINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas GIRARD, PhD</last_name>
      <email>nicolas.girard@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas GIRARD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie WISLEZ, MD</last_name>
      <email>marie.wislez@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie WISLEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie GOUNANT, MD</last_name>
      <email>valerie.gounant@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie GOUNANT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent FALLET, MD</last_name>
      <email>vincent.fallet@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent FALLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Ange MASSIANI, MD</last_name>
      <email>marieange.massiani@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Ange MASSIANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint-Malo</name>
      <address>
        <city>Saint-Malo</city>
        <zip>35420</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie TIERCIN, MD</last_name>
      <email>m.tiercin@ch-stmalo.fr</email>
    </contact>
    <investigator>
      <last_name>Marie TIERCIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Cécile METIVIER, MD</last_name>
      <email>ac.metivier@hopital-foch.com</email>
    </contact>
    <investigator>
      <last_name>Anne-Cécile METIVIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Tessier</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HUET Dimitri, MD</last_name>
      <email>dhuet@ahnac.com</email>
    </contact>
    <investigator>
      <last_name>Dimitri HUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer therapy</keyword>
  <keyword>last days of life</keyword>
  <keyword>optimization device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

